CT-721 |
| Katalog-Nr.GC35753 |
CT-721 ist ein potenter und zeitabhÄngiger Bcr-Abl-Kinase-Inhibitor mit einem IC50 von 21,3 nM fÜr die Wildtyp-Bcr-Abl-Kinase und besitzt AktivitÄten gegen chronische myeloische LeukÄmie (CML).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1388710-60-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities[1]. IC50: 21.3 nM (wild-type Bcr-Abl kinase)[1]
[1]. Sun Y, et al. CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia. J Cancer. 2017 Aug 23;8(14):2774-2784.
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *